Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1651 - 1700 of 1864 results
- Lentivirus mediated shRNA interference targeting MAT2B induces growth-inhibition and apoptosis in hepatocelluar carcinoma.
- Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy.
- Phase II Trial of Neoadjuvant Cisplatin, 5-Fluorouracil and Interferon-Alpha in Operable Squamous Cell Carcinoma of the Esophagus.
- A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
- 2-Thiazolylimino/Heteroarylimino-5-arylidene-4-thiazolidinones as New Agents with SHP-2 Inhibitory Action.
- Toxicology Profiles of A Novel p53-Armed Replication-Competent Oncolytic Adenovirus in Rodents, Felids and Nonhuman Primates.
- Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.
- Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
- Associations between the uptake of (111)In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
- Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity.
- OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions.
- Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity.
- Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy.
- Combination Therapy of Oral Fluoropyrimidine Anticancer Drug S-1 and Interferon Alpha for HCC Patients with Extrahepatic Metastases.
- A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
- Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
- Anti-CD30 diabody-drug conjugates with potent antitumor activity.
- Optimization of antibody binding to Fc{gamma}RIIa enhances macrophage phagocytosis of tumor cells.
- Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing.
- From the Cover: Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
- Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice.
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.
- Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines.
- Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
- Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.
- Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
- The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines.
- Expression of chemokine receptor CCR7 is associated with cervical lymph node metastasis of oral squamous cell carcinoma.
- Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin).
- Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
- Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
- Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
- Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
- TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
- Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells.
- Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
- CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
- Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity.
- A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
- Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
- hTERT-promoter driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.
- alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
- Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.
- Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1.
- Radioisotopic Localization of (90)Yttrium-Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin's Lymphoma.
- Effect of Ad-TIMP3 on biologic behavior of choriocarcinoma cells in vitro.
- Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
- Gene transfer using liposome-complexed adenovirus seems to overcome limitations due to coxsackievirus and adenovirus receptor-deficiency of cancer cells, both in vitro and in vivo.
- Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients.